Su epidemiología, clínica y tratamiento | 13 AGO 17

Síndrome de abstinencia neonatal a opiáceos

Descripción general del síndrome de abstinencia neonatal relacionado con el consumo materno de opiáceos
Autor/a: Karen McQueen, Jodie Murphy‑Oikonen N Engl J Med 2016; 375: 2468-79
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2: 141-58.

2. Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US children’s hospitals, 2004-2011. J Perinatol 2014; 34: 867-72.

3. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134(2): e547-61.

4. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract 2014; 9: 19.

5. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012; 307: 1934-40.

6. Patrick SW, Davis MM, Lehmann CU, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015; 35: 650-5.

7. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372: 2118-26.

8. Davies H, Gilbert R, Johnson K, et al. Neonatal drug withdrawal syndrome: cross-country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada. Arch Dis Child Fetal Neonatal Ed 2016; 101: F26-30.

9. Epstein RA, Bobo WV, Martin PR, et al. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol 2013; 23: 498-503.

10. Krans EE, Cochran G, Bogen DL. Caring for opioid-dependent pregnant women: prenatal and postpartum care considerations. Clin Obstet Gynecol 2015; 58: 370-9.

11. Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol 2015; 39: 561-5.

12. Ailes EC, Dawson AL, Lind JN, et al. Opioid prescription claims among women of reproductive age — United States, 2008–2012. MMWR Morb Mortal Wkly Rep 2015; 64: 37-41.

13. Yazdy MM, Desai RJ, Brogly SB. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet 2015; 4: 56-70.

14. Warren MD, Miller AM, Traylor J, Bauer A, Patrick SW. Implementation of a statewide surveillance system for neonatal abstinence syndrome — Tennessee, 2013. MMWR Morb Mortal Wkly Rep 2015; 64: 125-8.

15. Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med 2015; 373: 1789-90.

16. Gomes T, Juurlink DN. Opioid use and overdose: what we’ve learned in Ontario. Healthc Q 2016; 18: 8-11.

17. Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24: 252-8.

18. Jumah NA. Rural, pregnant, and opioid dependent: a systematic review. Subst Abuse 2016; 10: 35-41.

19. Wong S, Ordean A, Kahan M, et al. Substance use in pregnancy. J Obstet Gynaecol Can 2011; 33: 367-84.

20. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015; 135: 842-50.

21. ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119: 1070-6.

22. Visconti KC, Hennessy KC, Towers CV, Howard BC. Chronic opiate use in pregnancy and newborn head circumference. Am J Perinatol 2015; 32: 27-32.

23. Jansson LM, Velez ML. Infants of drug dependent mothers. Pediatr Rev 2011; 32: 5-12.

24. Lee J, Hulman S, Musci M Jr, Stang E. Neonatal abstinence syndrome: influence of a combined inpatient/outpatient methadone treatment regimen on the average length of stay of a Medicaid NICU population. Popul Health Manag 2015; 18: 392-7.

25. O’Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics 2009; 123(4): e614-21.

26. Worley J. Identification and management of prescription drug abuse in pregnancy. J Perinat Neonatal Nurs 2014; 28: 196-203.

27. Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics 2012; 129(2): e540-60.

28. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-31.

29. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 2014; 180: 673-86.

30. Gawronski KM, Prasad MR, Backes CR, Lehman KJ, Gardner DK, Cordero L. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. SAGE Open Med 2014; 2: 2050312114530282.

31. Kaltenbach K, Jones HE. Neonatal abstinence syndrome: presentation and treatment considerations. J Addict Med 2016; 10: 217-23.

32. Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014; 2014: 906723.

33. Siu A, Robinson CA. Neonatal abstinence syndrome: essentials for the practitioner. J Pediatr Pharmacol Ther 2014; 19: 147-55.

34. Newnam KM. The right tool at the right time: examining the evidence surrounding measurement of neonatal abstinence syndrome. Adv Neonatal Care 2014; 14: 181-6.

35. D’Apolito KC. Assessing neonates for neonatal abstinence: are you reliable? J Perinat Neonatal Nurs 2014; 28: 220-31.

36. Uebel H, Wright IM, Burns L, et al. Reasons for rehospitalization in children who had neonatal abstinence syndrome. Pediatrics 2015; 136(4): e811-20.

37. Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204(2): 139.e1-9.

38. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011; 5: 293-9.

39. Jansson LM, Garcia-Prats J, Kim S. Neonatal abstinence syndrome. Up To Date. August 3, 2016 (

40. Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr 2014; 165: 440-6.

41. Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Semin Perinatol 2016; 40: 203-12.

42. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309: 1821-7.

43. Smirk CL, Bowman E, Doyle LW, Kamlin COF. How long should infants at risk of drug withdrawal be monitored after birth? J Paediatr Child Health 2014; 50: 352-5.

44. Garcia AM. State laws regulating prescribing of controlled substances: balancing the public health problems of chronic pain and prescription painkiller abuse and overdose. J Law Med Ethics 2013; 41: Suppl 1: 42-5.

45. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol 2016; 128: 4-10.

46. Lendoiro E, Gonzalez-Colmenero E, Concheiro-Guisan A, et al. Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit 2013; 35: 296-304.

47. Narkowicz S, Płotka J, Polkowska Ż, Biziuk M, Namieśnik J. Prenatal exposure to substance of abuse: a worldwide problem. Environ Int 2013; 54: 141-63.

48. Clark L, Rohan A. Identifying and assessing the substance-exposed infant. MCN Am J Matern Child Nurs 2015; 40(2): 87-95.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023